Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390794 | 0.91 | TLR7 (0.46) | TLR7IL6 | |
| SCHEMBL4223870 | 0.91 | TLR7 (0.47) | TLR7 | |
| SCHEMBL1146459 | 0.91 | TLR7 (0.49) | TLR7 | |
| SCHEMBL2391153 | 0.90 | TLR7 (0.45) | TLR7IL6 | |
| SCHEMBL3359424 | 0.87 | TLR7 (0.50) | TLR7 | |
| SCHEMBL2389712 | 0.87 | TLR7 (0.52) | TLR7 | |
| SCHEMBL20275365 | 0.86 | TLR7 (0.53) | TLR7 | |
| SCHEMBL1501617 | 0.84 | TLR7 (0.56) | TLR7 | |
| SCHEMBL566854 | 0.84 | TLR7 (0.52) | TLR7 | |
| SCHEMBL2387756 | 0.84 | TLR7 (0.49) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143400-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| EP-1928876-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | AstraZeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007031726-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143400-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | IFNG, IFNAR1, IRF3 | TLR7 101/4885IL6 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.